THE INFLUENCE OF BIFIDOBACTERIUM ANIMALIS AND LECTIN OF B. SUBTILIS IMV B-7724 ON THE ANTITUMOR IMMUNE RESPONSE OF MICE WITH EHRLICH ADENOCARCINOMA

Authors

  • N. FEDOSOVA R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology of the NAS of Ukraine, Kyiv, Ukraine
  • N. CHEREMSHENKO R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology of the NAS of Ukraine, Kyiv, Ukraine
  • S. GOGOL R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology of the NAS of Ukraine, Kyiv, Ukraine
  • N. BEZDIENIEZHNYKH R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology of the NAS of Ukraine, Kyiv, Ukraine
  • V. TIKHONOV R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology of the NAS of Ukraine, Kyiv, Ukraine
  • I. VOYEYKOVA R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology of the NAS of Ukraine, Kyiv, Ukraine
  • V. KONOVALENKO R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology of the NAS of Ukraine, Kyiv, Ukraine
  • V. CHEKHUN R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology of the NAS of Ukraine, Kyiv, Ukraine

DOI:

https://doi.org/10.15407/exp-oncology.2024.03.228

Keywords:

Ehrlich adenocarcinoma, lectin of B. subtilis IMV B-7724, Bifidobacterium animalis, antitumor resistance

Abstract

Aim. To investigate the effect of bacteria of the genus Bifidobacterium and the extracellular metabolite of B. subtilis IMV B-7724 on the antitumor immune response of mice with a model tumor. Materials and Methods. The study was conducted on Balb/c mice with transplanted solid Ehrlich adenocarcinoma (ACE). Starting from the 2nd day after the transplantation of tumor cells, the animals of the experimental groups were treated with lectin of B. subtilis IMV B-7724 (s/c, 1 mg/kg of weight), Bifidobacterium animalis (per os, 7 × 105 CFU/mouse) or their combination. The immunological studies were performed on the 21st and 28th days of tumor growth. The functional activity of natural killer cells (NK), cytotoxic T-lymphocytes (CTL), as well as the ability of lymphocytes from the peripheral lymph nodes (PLN) to transform into blast cells under the influence of T- (Con A) and B-cell (LPS) mitogens were determined. Results. Administration of probiotic components to the mice with ACE led to the activation of innate immune responses, that is, to a significant increase in the cytotoxic activity of NK, especially in the case of their combined use. The NK cytotoxicity index was higher than that in the non-treated ACE-bearing mice and the intact control by 3.7 and 2.1 times, respectively (p < 0.05). Similarly, the highest specific cytotoxic activity of spleen lymphocytes was observed upon the combined use of the microbial preparations: the CTL cytotoxicity index was nearly 2.5-fold higher than in the non-treated ACE-bearing mice. The data on the ability of PLN lymphocytes to transform into blast cells under the influence of Con A and LPS indicated the preservation of the functional activity of lymphocytes in the animals of the experimental groups during ACE growth. Conclusion. Both B. animalis and lectin of B. subtilis IMV B-7724 have a significant influence on the effectors of the natural and adaptive immunity of mice with ACE. Their combined use was found to be the most effective.

References

Qiu Q, Lin Y, Ma Y, et al. Exploring the emerging role of the gut microbiota and tumor microenvironment in cancer immunotherapy. Front Immunol. 2021;11:612202. https://doi.org/10.3389/fimmu.2020.612202

Álvarez­Mercado AI, del Valle Cano A, Fernández MF, Fontana L. Gut microbiota and breast cancer: the dual role of microbes. Cancers. 2023;15:443. https://doi.org/10.3390/cancers15020443

Aghamajidi A, Maleki Vareki S. The effect of the gut microbiota on systemic and anti­tumor immunity and response to systemic therapy against cancer. Cancers (Basel). 2022;14(15):3563. https://doi.org/10.3390/cancers14153563

Sharma D, Gajjar D, Seshadri S. Understanding the role of gut microfloral bifidobacterium in cancer and its potential therapeutic applications. Microbiome Res Rep. 2024;3(1):3. https://doi.org/10.20517/mrr.2023.51

Shvets YuV, Lykhova OO, Chekhun VF. Human microbiota and breast cancer. Exp Oncol. 2022;44(2):95­106. https:// doi.org/10.32471/exp­oncology.2312­8852.vol­44­no­2.17855

Bernardo G, Le Noci V, Di Modica M, et al. The emerging role of the microbiota in breast cancer progression. Cells.

;12(15):1945. https://doi.org/10.3390/cells12151945

Kaźmierczak­Siedlecka K, Daca A, Fic M, et al. Therapeutic methods of gut microbiota modification in colorec­ tal cancer management­fecal microbiota transplantation, prebiotics, probiotics, and synbiotics. Gut Microbes. 2020;11(6):1518­1530. https://doi.org/10.1080/19490976.2020.1764309

Li W, Deng Y, Chu Q, Zhang P. Gut microbiome and cancer immunotherapy. Cancer Lett. 2019;447:41­47. https:// doi.org/10.1016/j.canlet.2019.01.015

Legesse Bedada T, Feto TK, Awoke KS, et al. Probiotics for cancer alternative prevention and treatment. Biomed Pharmacother. 2020;129:110409. https://doi.org/10.1016/j.biopha.2020.110409

Akbaba M, Gökmen GG, Kışla D, Nalbantsoy A. In vivo investigation of supportive immunotherapeutic combi­ nation of Bifidobacterium infantis 35624 and doxorubicin in murine breast cancer. Probiotics Antimicrob Proteins. 2023;15(4):880­888. https://doi.org/10.1007/s12602­021­09899­w

Zhao H, Li D, Liu J, et al. Bifidobacterium breve predicts the efficacy of anti­PD­1 immunotherapy combined with chemotherapy in Chinese NSCLC patients. Cancer Med. 2023;12(5):6325­6336. https://doi.org/10.1002/cam4.5312

Ferdous UT, Shishir MA, Khan SN, Hoq MM. Bacillus spp.: Attractive sources of anti­cancer and anti­proliferative biomolecules. Microbial Bioactives. 2018;1(1):033­045. https://doi.org/10.25163/microbbioacts.11005B0408130818

Aimaier R, Li H, Cao W, et al. The secondary metabolites of Bacillus subtilis strain Z15 induce apoptosis in hepatocel­ lular carcinoma cells. Probiotics Antimicrob Proteins. 2023. https://doi.org/10.1007/s12602­023­10181­4

Chumak AV, Fedosova NI, Cheremshenko NL, et al. Effect of B.subtilis ІМV B­7724 lectin on the activity of effec­ tors of cellular antitumor immunity of mice with Lewis lung carcinoma. Exp Oncol. 2023;45(3):328­336. https://doi. org/10.15407/exp­oncology/2023.03.328

European Convention for the Protection of Vertebrate Animals used for Experimental and other Scientifi Purposes ETS 123. Protection of Vertebrate Animals, 18.III.1986. 48. https://norecopa.no/media/2iydns5h/ets­123­original.pdf

Radulski DR, Stipp MC, Galindo CM, Acco A. Features and applications of Ehrlich tumor model in cancer studies: a literature review. Transl Breast Cancer Res. 2023;4:22. https://doi.org/10.21037/tbcr­23­32

Fedosova NI, Cheremshenko NL, Hetman KI, et al. Physicochemical and cytotoxicity properties of Bacillus subtilis

ІМV В­7724 extracellular lectin. Mikrobiol Z. 2021;83:39­48. https://doi.org/10.15407/microbiolj83.01.039

Stefanov OV. Doklinichni doslidzhennya likarskykh zasobiv [Preclinical studies of drugs]. Kyiv: Avitsena; 2001 (in Ukrainian).

Van de Loosdrecht AA, Beelen RH, Ossenkoppele GJ, et al. A tetrazolium­based colorimetric MTT assay to quan­ titate human monocyte mediated cytotoxicity against leukemic cells from cell lines and patients with acute myeloid leukemia. J Immunol Methods. 1994;174:311­320.

Anuradha B, Santosh CM, Hari Sai Priya V, et al. Age­related waning of in vitro Interferon­gamma levels against r32kD­ aBCG in BCG vaccinated children. J Immune Based Ther Vaccines. 2007;7(5):8. https://doi.org/10.1186/1476­8518­5­8

Fedosova NI, Cheremshenko NL, Tikhonov VG, et al. Antitumor effectiveness of the combined application of bac­ teria of the genus Bifidobacterium and B. subtilis IMV B­7724 lectin. Oncology. 2024;26(2):133­138. https://doi. org/10.15407/oncology.2024.02.133 (in Ukrainian).

Procaccianti G, Roggiani S, Conti G, et al. Bifidobacterium in anticancer immunochemotherapy: friend or foe? Mi- crobiome Res Rep. 2023;2(3):24. https://doi.org/10.20517/mrr.2023.23

Gopalakrishnan V, Helmink BA, Spencer CN, et al. The influence of the gut microbiome on cancer, immunity, and cancer immunotherapy. Cancer Cell. 2018;33(4):570­580. https://doi.org/10.1016/j.ccell.2018.03.015

Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD­1­based immunotherapy against epithelial tumors. Science. 2018;359(6371):91­97 https://doi.org/10.1126/science.aan3706

Choi M, Lee Y, Lee NK, et al. Immunomodulatory effects by Bifidobacterium longum KACC 91563 in mouse spleno­ cytes and macrophages. J Microbiol Biotechnol. 2019;29(11):1739­1744. https://doi.org/10.4014/jmb.1812.12002

Hayase E, Jenq RR. Role of the intestinal microbiome and microbial­derived metabolites in immune checkpoint blockade immunotherapy of cancer. Genome Med. 2021;13(1):107. https://doi.org/10.1186/s13073­021­00923­w

Downloads

Published

19.12.2024

How to Cite

FEDOSOVA, N., CHEREMSHENKO, N., GOGOL, S., BEZDIENIEZHNYKH, N., TIKHONOV, V., VOYEYKOVA, I., … CHEKHUN, V. (2024). THE INFLUENCE OF BIFIDOBACTERIUM ANIMALIS AND LECTIN OF B. SUBTILIS IMV B-7724 ON THE ANTITUMOR IMMUNE RESPONSE OF MICE WITH EHRLICH ADENOCARCINOMA. Experimental Oncology, 46(3), 228–236. https://doi.org/10.15407/exp-oncology.2024.03.228

Issue

Section

Original contributions